Kura in Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

 Kura Oncology Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura’s menin inhibitor, ziftomenib, in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-rearranged or NPM1-mutant acute leukemia.

In partnership with the PedAL Initiative, LLS will serve as the coordinating sponsor in North America and the Princess Máxima Center for Pediatric Oncology in Utrecht, the Netherlands, will serve as the coordinating sponsor in Europe. PedAL is a pioneering global master clinical trial for Pediatric Acute Leukemia, founded and led by LLS, which aims to advance more effective, safer treatments with fewer long-term side effects, for children with blood cancer.

https://www.biospace.com/article/releases/kura-oncology-s-menin-inhibitor-ziftomenib-selected-for-the-leukemia-and-lymphoma-society-s-pediatric-acute-leukemia-pedal-master-clinical-trial/